The Netherlands
Plasmacure, founded in 2013 and headquartered in The Netherlands, is at the forefront of transforming complex wound care with its pioneering technology. The healthcare startup is focused on addressing the persistent challenge of chronic wounds, which affect millions worldwide by impairing mobility and increasing healthcare costs.
Its flagship product, PLASOMA, employs a patented cold plasma system to accelerate wound healing. Clinically validated through a peer-reviewed randomized controlled trial, PLASOMA demonstrated a 2.5x greater efficacy than traditional treatments while reducing healthcare costs by over 40% and clinician workload by more than 50%. With less than a two-minute treatment time, it integrates seamlessly into current care, both in clinics and at home.
Already available in Europe with a CE-marked Class IIb medical device status, Plasmacure is preparing to expand into the United States and China. The company recently raised a €6.00M Series A led by Oost NL, Venture Medical, LLC, Coöperatie VGZ, Noaber, Stichting Triade, and the EIC Fund, a testament to its growth potential and market impact. Such strategic investments position Plasmacure to redefine the landscape of wound care globally.
